Long-term evaluation of ifosfamide-related nephrotoxicity in children

Journal of Clinical Oncology

Volumn 27, Issue 32, 2009, Pages 5350-5355

  Oberlin, Odile ^a   Fawaz, Oumaya ^a   Rey, Annie ^a   Niaudet, Patrick ^a   Ridola, Vita ^a   Orbach, Daniel ^a   Bergeron, Christophe ^a   Defachelles, Annie Sophie ^a   Gentet, Jean Claude ^a   Schmitt, Claudine ^a   Rubie, Hervé ^a   Munzer, Martine ^a   Plantaz, Dominique ^a   Deville, Anne ^a   Minard, Veronique ^a   Corradini, Nadège ^a   Leverger, Guy ^a   De Vathaire, Florent ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CALCIUM; CARBOPLATIN; CISPLATIN; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; MESNA; METHOTREXATE; PHOSPHATE; VINCRISTINE; ALKYLATING AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; BICARBONATE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CANCER RADIOTHERAPY; CANCER RELAPSE; CHILD; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EWING SARCOMA; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INCIDENCE; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; KIDNEY TUBULE FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OSTEOSARCOMA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RHABDOMYOSARCOMA; RISK FACTOR; SOFT TISSUE SARCOMA; TREATMENT DURATION; TUMOR LOCALIZATION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FOLLOW UP; KIDNEY; KIDNEY DISEASE; KIDNEY FUNCTION TEST; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; SARCOMA; TIME;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RHABDOMYOSARCOMA; RISK FACTORS; SARCOMA; SARCOMA, EWING'S; TIME FACTORS;

EID: 73949098182     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.5257     Document Type: Article

References (37)

1. Bryant BM, Jarman M, Ford HT, et al: Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 2:657-659, 1980
2. Carli M, Passone E, Perilongo G, et al: Ifosfamide in pediatric solid tumors. Oncology 65:99-104, 2003
3. Skinner R, Sharkey IM, Pearson AD, et al: Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11:173-190, 1993
4. Bramwell VH, Mouridsen HT, Santoro A, et al: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311-321, 1987
5. Jenney M, Morris-Jones P, Gattamaneni HR, et al: Ifosfamide for children with solid tumours. Lancet 335:1398-1400, 1990
6. Crist WM, Anderson JR, Meza JL, et al: Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 19:3091-3102, 2001
7. Heney D, Lewis IJ, Bailey CC: Acute ifosfamide-induced tubular toxicity. Lancet 2:103-104, 1989
8. Moncrieff M, Foot A: Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol 23:121-122, 1989
9. Skinner R, Pearson AD, Price L, et al: Hypophosphataemic rickets after ifosfamide treatment in children. BMJ 298:1560-1561, 1989
10. Suarez A, McDowell H, Niaudet P, et al: Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: An International Society of Pediatric Oncology report. J Clin Oncol 9:2177-2182, 1991
11. Goren MP, Wright RK, Pratt CB, et al: Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cisdiamminedichloroplatinum(II) therapy. Cancer Res 47:1457-1460, 1987
12. Pratt CB, Meyer WH, Jenkins JJ, et al: Ifosfamide, Fanconi's syndrome, and rickets. J Clin Oncol 9:1495-1499, 1991
13. Loebstein R, Atanackovic G, Bishai R, et al: Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 39:454-461, 1999
14. Stöhr W, Patzer L, Paulides M, et al: Growth impairment after ifosfamide-induced nephrotoxicity in children. Pediatr Blood Cancer 48:571-576, 2007
15. Patterson WP, Khojasteh A: Ifosfamide-induced renal tubular defects. Cancer 63:649-651, 1989
16. Skinner R, Cotterill SJ, Stevens MC: Risk factors for nephrotoxicity after ifosfamide treatment in children: A UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer 82:1636-1645, 2000
17. Lee BS, Lee JH, Kang HG, et al: Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatr Nephrol 16:796-799, 2001
18. Rossi R, Godde A, Kleinebrand A, et al: Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: Analysis of 120 patients. J Clin Oncol 12:159-165, 1994
19. Raney B, Ensign LG, Foreman J, et al: Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. Am J Pediatr Hematol Oncol 16:286-295, 1994
20. McCune JS, Friedman DL, Schuetze S, et al: Influence of age upon Ifosfamide-induced nephrotoxicity. Pediatr Blood Cancer 42:427-432, 2004
21. Haycock GB: Creatinine, body size and renal function. Pediatr Nephrol 3:22-24, 1989
22. Schwartz GJ, Haycock GB, Edelman C, et al: A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259-263, 1976
23. Gault MH, Longerich LL, Harnett JD, et al: Predicting glomerular function from adjusted serum creatinine. Nephron 62:249-256, 1992
24. Bergón E, Granados R, Fernandez-Segoviano P, et al: Classification of renal proteinuria: A simple algorithm. Clin Chem Lab Med 40:1143-1150, 2002
25. Guignard JSF: Laboratory investigations, in Avner ED, Harmon WE, Niaudet P (eds): Pediatric Nephrology. Philadelphia, PA, Lippincott Williams & Wilkins, 2004, pp 399-424
26. Skinner R, Pearson AD, Coulthard MG, et al: Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol 28:81-92, 1991
27. Ali F, Langman C: Disorders of mineral metabolism, in Kher K, Makker SP, Schnaper HW (eds): Pediatric Nephrology. Andover, United Kingdom, Informa, 2006, pp 37-60
28. Stark H, Eisenstein B, Tieder M, et al: Direct measurement of TP/GFR: A simple and reliable parameter of renal phosphate handling. Nephron 44:125-128, 1986
29. Burk CD, Restaino I, Kaplan BS, et al: Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. J Pediatr 117:331-335, 1990
30. Stöhr W, Paulides M, Bielack S, et al: Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: A report from the Late Effects Surveillance System. Pediatr Blood Cancer 48:447-452, 2007
31. Rossi R, Pleyer J, Schafers P, et al: Development of ifosfamide-induced nephrotoxicity: Prospective follow-up in 75 patients. Med Pediatr Oncol 32: 177-182, 1999
32. Skinner R, Pearson AD, English MW, et al: Risk factors for ifosfamide nephrotoxicity in children. Lancet 348:578-580, 1996
33. Skinner R, Pearson AD, Price L, et al: The influence of age on nephrotoxicity following chemotherapy in children. Br J Cancer Suppl 18:S30-S35, 1992
34. Van Gool S, Brock P, Wijndaele G, et al: Reversible hypophosphatemic rickets following ifosfamide treatment. Med Pediatr Oncol 20:254-257, 1992
35. Caron HN, Abeling N, van Gennip A, et al: Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Med Pediatr Oncol 20:42-47, 1992
36. English MW, Skinner R, Pearson AD, et al: The influence of ifosfamide scheduling on acute nephrotoxicity in children. Br J Cancer 75:1356-1359, 1997
37. Ridola V, Defachelles AS, Schmitt C, et al: Ifosfamide versus cyclophosphamide: Long term gonadal effects in 166 male survivors of childhood cancer. J Clin Oncol 25:529s, 2007 (suppl; abstr 9515)